PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway

PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway

Abstract Epidermal growth factor receptor (EGFR)-targeted drugs (erlotinib, etc.) are used to treat multiple types of tumours. EGFR is highly expressed in most triple-negative breast cancer (TNBC) patients. However, only a small proportion of TNBC patients benefit from EGFR-targeted drugs in clinica...

Full description

Bibliographic Details
Main Authors: Yuanzhen Ma, Zhiyu Fang, Hongning Zhang, Yijun Qi, Yuke Mao, Junfang Zheng
Format: Article
Language:English
Published: Nature Publishing Group 2024-04-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-024-06502-2

Internet

https://doi.org/10.1038/s41419-024-06502-2

Similar Items